Fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in non-resectable pancreatic cancer patients.
Phase 2
Recruiting
- Conditions
- Pancreatic cancer
- Registration Number
- JPRN-UMIN000005808
- Lead Sponsor
- Yokohama City University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
1.Age of 76 years or older. 2.Endocrine or acinar pancreatic carcinoma. 3.Brain metastases. 4.Another major cancer. 5.Active infection. 6.Chronic diarrhea. 7.Cardiac disease 8.Pregnancy or breast-feeding 9.In the UGT1A1 allele, UGT1A1 (*)28/(*)28 genotype UGT1A1 (*)28/(*)6 genotype UGT1A1 (*)6/(*)6 genotype
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety and feasibility in FOLFIRINOX.
- Secondary Outcome Measures
Name Time Method Response rate, survival rate, progression-free survival rate,and toxicity.